Guangzhou Baiyunshan Pharmaceutical Holdings (00874) branch chemical pharmaceutical factory "Drug Production License" changes

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Pharmaceutical Group Co., Ltd. (hereinafter referred to as "chemical pharmaceutical factory"), has received the "Drug Production License" issued by the Guangdong Provincial Drug Administration, approving the addition of new production addresses, production workshops, production lines, and production scope for the chemical pharmaceutical factory, and passing the inspection on drug production quality management standards. The Guangdong Provincial Drug Administration approved the addition of new production addresses for the chemical pharmaceutical factory as "Guangzhou Baiyunshan Pharmaceutical Holdings Road, north side of Jiangwan Road, Fushan Industrial Park, Doumen District, Zhuhai, addition of new production workshop as "Zhuhai Workshop, addition of new production line as "102 Production Line", and addition of new production scope as "raw materials (Cefaclor)". The drug production quality management standards inspection was conducted on the raw materials (Cefaclor) [Zhuhai Workshop 102 Production Line (production address: north side of Jiangwan Road, Fushan Industrial Park, Doumen District, Zhuhai, Guangzhou Baiyunshan Pharmaceutical Holdings Road)] and raw materials (Sildenafil citrate) [Beisha Workshop Synthesis Production Line 1 (production address: Beisha Industrial Area, Lishui Town, Nanhai District, Foshan), 202 Pilot Workshop 202 Pilot Production Line, 201 Workshop 201 Production Line, 203 Workshop 203 Production Line (production address: 78 Tongbao Road, Tonghe Street, Baiyun District, Guangzhou)], and the scope of this inspection "raw materials (Sildenafil citrate, Cefaclor)" complies with the requirements of the "Drug Production Quality Management Standards (Revised in 2010)". The addition of new production addresses, production workshops, production lines, and production scope for the chemical pharmaceutical factory, and passing the drug production quality management standards inspection, are beneficial for increasing production capacity, improving production efficiency, enhancing intelligent and digital levels, and meeting market demand. This acquisition of the "Drug Production License" has no significant impact on the company's current performance.